Described herein is a compound of the formula ##STR1## wherein Ar' is a mono or bicyclic aromatic or heteroaromatic radical substituted with one to three substituents selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.8)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; R.sup.1 is hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio; R.sup.2 is phenyl, naphthyl or (C.sub.3 -C.sub.12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.8)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.8)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; X is --(C.dbd.O)--; or a pharmaceutically acceptable salt racemate, optical isomer or solvate thereof.

Se describe adjunto un compuesto del ## del ## STR1 del fórmula en donde Ar ' es un radical aromático o heteroaromatic mono o bicíclico substituido con un a tres sustitutos seleccionados del hidrógeno que consiste en del grupo, (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.8)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl o halo; R.sup.1 es hidrógeno, (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio; R.sup.2 es fenilo, naftílico o (C.sub.3 - C.sub.12)cycloalkyl substituido con un o dos sustitutos seleccionados del hidrógeno que consiste en del grupo (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.8)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl o halo; R.sup.3 se selecciona del hidrógeno que consiste en del grupo, (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.8)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl o halo; X es -- (C.dbd.O) --; o un racemate farmacéutico aceptable de la sal, un isómero óptico o un solvate de eso.

 
Web www.patentalert.com

< Osmotic device within an osmotic device

< Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors

> Long acting antidepressant microparticles

> Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia

~ 00067